Shares for Myriad Genetics took a nosedive as pessimism surrounds the company in its fight against a rival’s alleged infringement on Myriad patents, say reports.
The company lost a bid to have its rival’s products blocked while the lawsuit is pending. Myriad is suing Ambry Genetics for allegations the company violated Myriad patents, but US District Judge Robert Shelby said the company is unlikely to emerge successful in the cases.
Reports say there are “substantial questions,” as the judge put it, as to whether the property in question actually constitute a patent.
Reports say the genetics company claims Ambry infringed on patents involving tests that detect breast and ovarian cancer.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI